Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.54 |
| ▸ | TSHR | P16473 | 1/20 | 0.54 |
| ▸ | NOS1 | P29475 | 1/20 | 0.53 |
| ▸ | S1PR1 | P21453 | 11/20 | 0.50 |
| ▸ | MAOB | P27338 | 2/20 | 0.47 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.45 |
| ▸ | HTR7 | P34969 | 1/20 | 0.45 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.44 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.44 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL989636 | 0.89 | ALDH1A1 (0.67) | ALDH1A1TSHRNOS1HTR7CHRNB2 | |
| SCHEMBL7825553 | 0.83 | ALDH1A1 (0.50) | ALDH1A1TSHRNOS1HTR7CHRNB2 | |
| SCHEMBL26985997 | 0.82 | ALDH1A1 (0.53) | ALDH1A1TSHRS1PR1MAOB | |
| SCHEMBL21674318 | 0.82 | S1PR1 (0.54) | S1PR1ENPP2CHRNB2CHRNA4 | |
| SCHEMBL1876155 | 0.81 | ALDH1A1 (0.48) | ALDH1A1TSHRNOS1CHRNB2CHRNA4 | |
| SCHEMBL2486885 | 0.81 | TAAR1 (0.58) | ALDH1A1TSHRNOS1HTR7HRH3 | |
| SCHEMBL123838 | 0.81 | TSHR (0.61) | TSHRNOS1S1PR1ENPP2 | |
| SCHEMBL9872121 | 0.80 | SLC6A2 (0.48) | ALDH1A1TSHRNOS1HTR7 | |
| SCHEMBL13462516 | 0.80 | ALDH1A1 (0.56) | ALDH1A1TSHRNOS1HTR7CHRNB2 | |
| SCHEMBL22764855 | 0.79 | S1PR1 (0.55) | TSHRS1PR1ENPP2HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119170820-A | Proton exchange membrane and preparation method thereof | 苏州拓际新材料科技有限公司 | 2024-12-20 | — | — | CN | claimed |
| CN-119170820-A | Proton exchange membrane and preparation method thereof | 苏州拓际新材料科技有限公司 | 2024-12-20 | — | — | CN | disclosed |
| US-20230132298-A1 | OXABOROLE ESTERS AND USES THEREOF | ANACOR PHARMACEUTICALS, LLC | 2023-04-27 | — | — | US | disclosed |
| US-20230132298-A1 | OXABOROLE ESTERS AND USES THEREOF | ANACOR PHARMACEUTICALS, LLC | 2023-04-27 | — | — | US | disclosed |
| US-11578087-B2 | Oxaborole esters and uses thereof | ANACOR PHARMACEUTICALS, INC. (US) | 2023-02-14 | — | — | US | disclosed |
| EP-3578562-B1 | L-VALINATE AMIDE BENZOXABOROLE DERIVATIVES FOR THE TREATMENT OF PARASITIC DISEASES | ANACOR PHARMACEUTICALS INC (US) | 2021-06-23 | — | — | EP | disclosed |
| US-20210101916-A1 | OXABOROLE ESTERS AND USES THEREOF | ANACOR PHARMACEUTICALS, INC. | 2021-04-08 | — | — | US | disclosed |
| US-10961202-B2 | Bis-benzimidazole compounds and methods of using the same | THE SCRIPPS RESEARCH INSTITUTE (US) | 2021-03-30 | — | — | US | disclosed |
| US-10961202-B2 | Bis-benzimidazole compounds and methods of using the same | THE SCRIPPS RESEARCH INSTITUTE (US) | 2021-03-30 | — | — | US | disclosed |
| US-10882872-B2 | Oxaborole esters and uses thereof | ANACOR PHARMACEUTICALS, INC. (US) | 2021-01-05 | — | — | US | disclosed |
| WO-2017040449-A1 | TRIAZOLOPYRIDINE INHIBITORS OF MYELOPEROXIDASE | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-03-09 | — | — | WO | disclosed |
| EP-1121361-B1 | PYRAZOLO-TRIAZINE DERIVATIVES AS LIGANDS FOR GABA RECEPTORS | MERCK SHARP & DOHME (GB) | 2007-08-29 | — | — | EP | disclosed |
| US-6476030-B1 | Pyrazolo-triazine derivatives as ligands for GABA receptors | MERCK SHARP & DOHME LTD. | 2002-11-05 | — | — | US | disclosed |
| EP-1121361-A1 | PYRAZOLO-TRIAZINE DERIVATIVES AS LIGANDS FOR GABA RECEPTORS | Merck Sharp & Dohme Limited (GB) | 2001-08-08 | — | — | EP | disclosed |
| WO-2000023449-A1 | PYRAZOLO-TRIAZINE DERIVATIVES AS LIGANDS FOR GABA RECEPTORS | MERCK SHARP & DOHME LIMITED (GB) | 2000-04-27 | — | — | WO | disclosed |
| US-5021429-A | Histamine h2-antagonists; antisecretory-antiallergen agent; skin disorders and peptic ulcers | ALLEN & HANSBURYS LIMITED (GB) | 1991-06-04 | — | — | US | disclosed |
| US-4496567-A | HSITAMINE H2 ANTAGONISTS | SMITH KLINE & FRENCH LABORATORIES LIMITED (GB) | 1985-01-29 | — | — | US | disclosed |
| EP-0013071-B1 | PYRIMIDINONE DERIVATIVES, PROCESSES FOR PREPARING THEM AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | SMITH KLINE & FRENCH LABORATORIES LIMITED (GB) | 1983-11-16 | — | — | EP | disclosed |
| EP-0013071-A1 | Pyrimidinone derivatives, processes for preparing them and pharmaceutical compositions containing them | SMITH KLINE & FRENCH LABORATORIES LIMITED (GB) | 1980-07-09 | — | — | EP | disclosed |
| WO-1980000966-A1 | NEW HISTAMINE H2-ANTAGONISTS | SMITH KLINE FRENCH LAB (GB) | 1980-05-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10961202-B2 | Bis-benzimidazole compounds and methods of using the same | HNRNPH1, HNRNPH3, HNRNPUL2 | ALDH1A1 3412/4885TSHR 3601/4885NOS1 3723/4885 |
| US-20230132298-A1 | OXABOROLE ESTERS AND USES THEREOF | OXA1L, HSD17B12, OXER1 | ALDH1A1 585/4885TSHR 2439/4885NOS1 2432/4885 |
| US-10882872-B2 | Oxaborole esters and uses thereof | OXA1L, HSD17B12, OXER1 | ALDH1A1 585/4885TSHR 2439/4885NOS1 2432/4885 |
| US-20210101916-A1 | OXABOROLE ESTERS AND USES THEREOF | OXA1L, HSD17B12, OXER1 | ALDH1A1 585/4885TSHR 2439/4885NOS1 2432/4885 |
| US-11578087-B2 | Oxaborole esters and uses thereof | OXA1L, HSD17B12, OXER1 | ALDH1A1 585/4885TSHR 2439/4885NOS1 2432/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.